Stay updated on Ecztra 4: Tralokinumab Drug Interaction Clinical Trial
Sign up to get notified when there's something new on the Ecztra 4: Tralokinumab Drug Interaction Clinical Trial page.

Latest updates to the Ecztra 4: Tralokinumab Drug Interaction Clinical Trial page
- Check5 days agoChange DetectedDrug/substrate details and other study logistics were removed. Specifically, multiple medications and trial-related sections such as the DDI components, study plan, eligibility criteria, and locations are no longer shown.SummaryDifference18%

- Check12 days agoChange DetectedA minor revision note was updated from v3.4.1 to v3.4.2; no clinical content or page structure changes are apparent. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision bumped from v3.4.0 to v3.4.1. No visible changes to study details or other essential page content.SummaryDifference0.0%

- Check33 days agoChange DetectedUI updates include show/hide glossary toggles and minor label/version changes (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check41 days agoChange DetectedA minor site revision updated the page to include Revision: v3.3.4 and remove Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check70 days agoChange DetectedThe page now consolidates site information under a general Locations heading, listing Arkansas, California, Florida, Massachusetts, South Carolina, and Virginia. Per-state location sections were removed, and the page revision updated to v3.3.3.SummaryDifference0.7%

Stay in the know with updates to Ecztra 4: Tralokinumab Drug Interaction Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ecztra 4: Tralokinumab Drug Interaction Clinical Trial page.